I don’t know for sure but suspect that the 70% crossing of the blood brain barrier is precisely that and relates to pharmacokinetics and transfer rate into the brain rather than receptor occupancy. If true in theory I image you could achieve full receptor occupancy in the brain, it’s just a matter of dosing and pharmacokinetics at that point. Cytodyn has very little experience with IV infusion route dosing, I am only aware of it for the Covid study in Brazil. You would not be bound by the current practical limit of 700 mg SQ…I think that is a 2mL volume, a pretty large volume to be pushing in SQ…IV infusion could entertain much higher dosing as determined through further study based on indication, leading to more rapid peak concentrations. Critical COVID patients really would have benefited significantly by IV dosing and rapid RO…I think the severe/critical COVID study might have seen spectacular results if that were the case.